drugset
drugset / Trial / NCT06601504

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT06601504 ↗

Phase 2 Active not recruiting 61 enrolled Hutchmed
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

Timeline

Start
2024-11-05
Primary completion
2026-05-12
Completion
2026-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HMPL-760 Unknown — Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Oxaliplatin Small molecule 100 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma